B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion...

MarketOptimizer.org adds “OpportunityAnalyzer: Non-Hodgkin’s B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018” to its store. Overview of B-cell NHL, including epidemiology, etiology,...(PRWeb September 01, 2014)Read the full story at http://www.prweb.com/releases/2018-non-hodgkins-b-cell/lymphoma-market-analysis/prweb12135505.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news

Related Links:

AbstractPurpose of ReviewIMiDs are a class of biologic agents with immunomodulatory, anti-angiogenic, and direct anti-cancer activities. This review summarizes current data on clinical development and application of IMiDs in non-Hodgkin lymphoma (NHL) subtypes, focusing primarily on lenalidomide, with additional discussion on managing common side effects.Recent FindingsImproved upon the prototype thalidomide, the second-generation compound lenalidomide has enhanced immunological and anti-cancer properties with fewer side effects, while next-generation small molecule cereblon/E3 ubiquitin ligase modulator CC-122 is in early...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
ConclusionsBaseline TMTV and TLG are both strong independent prognostic factors for pediatric B-NHL and provide a potential approach to aid in risk sub-stratification, especially in patients with high-risk disease.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Conclusion: When clinicians encounter a lesion associated with mandibular canal widening, they should immediately consider these entities in the differential diagnosis. Doing so will help dentists make more accurate diagnoses and develop better treatment plans based on patients' radiographs. PMID: 31281785 [PubMed]
Source: Imaging Science in Dentistry - Category: Dentistry Tags: Imaging Sci Dent Source Type: research
CONCLUSIONS: NRP-1 exhibited higher expression in lymphomas, and it was positively expressed in EBV-positive lymphomas. Moreover, highly expressed NRP-1 can be used as an undesirable independent prognostic factor in NHL. PMID: 31282408 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
u C, Doshi P, Pérez-Galán P Abstract CD38 is expressed in several types of non-Hodgkin lymphoma and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody approved for the treatment of relapsed/refractory multiple myeloma. It has also demonstrated clinical activity in Waldenstrom macroglobulinaemia and amyloidosis. Here, we have evaluated the activity and mechanism of action of daratumumab in preclinical in vitro and in vivo models of mantle cell lymphoma, follicular lymphoma and diffuse large B cell lymphoma, as monotherapy or in comb...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
CONCLUSIONS: In in-silico experiments, optimal protocols achieve significant gains over standard protocols when considering overall survival probabilities. Our optimization algorithm enables us to efficiently tackle this numerical problem with a large dimensionality. The in-vivo implications of our in-silico results remain to be explored. PMID: 31302209 [PubMed - as supplied by publisher]
Source: Mathematical Biosciences - Category: Statistics Authors: Tags: Math Biosci Source Type: research
SAN FRANCISCO - A California man on June 21 sued Monsanto Co. in California federal court, contending that he has developed non-Hodgkin lymphoma (NHL) as a result of exposure to glyphosate, the active ingredient in the herbicide Roundup, which he alleges Monsanto has misrepresented as a safe product (Saul Cohen v. Monsanto Company, No. 19-3632, N.D. Calif.).
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - Category: Medical Law Source Type: news
Conditions:   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma Intervention:   Combination Product: CD19 CART Sponsors:   Chinese PLA General Hospital;   Shenzhen University;   Shenzhen University General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: Guideline compliance was very low. Although not statistically significant, there was a trend for reduced CINV and improved disease control for triple versus double antiemetics, suggesting that triple antiemetics should be considered for HEC, especially in young female patients with non-Hodgkin lymphoma receiving CHOP-like regimens.
Source: In Vivo - Category: Research Authors: Tags: Clinical Studies Source Type: research
We present a case of an appearance of periaortic infiltration after successful endovascular treatment which turned out to be of malignant origin. PMID: 31271346 [PubMed - as supplied by publisher]
Source: VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases - Category: Surgery Authors: Tags: Vasa Source Type: research
More News: Epidemiology | Lymphoma | Non-Hodgkin's Lymphoma | Pharmaceuticals